Emergent BioSolutions Anticipates 2nd Quarter BioThrax Revenues of Approximately $20 Million Based on Accelerated Delivery to Department of Defense
Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced today that, pursuant to the terms of an amended contract with the U.S. Department of Defense (DoD), it anticipates...
Emergent BioSolutions to Present at the Jefferies & Company Healthcare Conference
June 20, 2007--Emergent BioSolutions Inc. (NYSE: EBS), a biopharmaceutical company, announced today that it will present at the Jefferies & Company Annual Healthcare Conference on June 27, 2007 at...
Emergent BioSolutions Announces Expansion of Board of Directors and Appointment of Dr. Sue Bailey to the Company’s Board of Directors
Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced today that at a regularly scheduled meeting of its board of directors the board passed a resolution authorizing the...
Emergent BioSolutions Announces Results from Annual Meeting of Stockholders
Emergent BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced today the results of the company's 2007 annual meeting of stockholders, which took place today at the Hyatt Regency...
Emergent BioSolutions to Hold Annual Meeting of Stockholders
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will hold its Annual Meeting of Stockholders on Thursday June 14, 2007 beginning at 10:00 am Eastern Time at the Hyatt Regency Bethesda,...
Emergent BioSolutions to Present at Morgan Keegan Homeland Security Technology Conference 2007
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will present at the Morgan Keegan Homeland Security Technology 2007 Conference on May 22, 2007 at 2:10 pm Eastern Time at The New York...
Emergent BioSolutions Announces Management Changes
Emergent BioSolutions Inc. (NYSE:EBS) announced today the consolidation of the president and chief operating officer position. With this change, Daniel J. Abdun-Nabi, the company's president, will...
Emergent BioSolutions Reports Financial Results for First Quarter 2007
Emergent BioSolutions Inc. (NYSE:EBS) announced today that total revenues for the first quarter of 2007 grew by $14.2 million to $26.4 million from $12.2 million in the comparable period in 2006,...
Emergent BioSolutions to Present at The Rodman and Renshaw 4th Annual Global Healthcare Conference
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it will present at the Acumen BioFin Rodman and Renshaw 4th Annual Global Healthcare Conference on May 15, 2007 at 12:15 pm Central...
Emergent BioSolutions to Release First Quarter 2007 Financial Results on May 9, 2007
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it will report financial results for the first quarter 2007 on Wednesday, May 9, 2007, before market...
Emergent BioSolutions Announces That Department of Health and Human Services and Department of Defense Issued Notices of Intent to Procure up to a Combined 22.75 Million Doses of BioThrax(R)(Anthrax Vaccine Adsorbed)
Emergent BioSolutions Inc. today announced that the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense (DoD) issued two separate notices of intent to procure up to...
Emergent BioSolutions Reports Financial Results for 2006
Emergent BioSolutions Inc. (NYSE: EBS) announced today that total revenues for 2006 grew 17 percent to $152.7 million from $130.7 million in 2005, driven by the delivery of over 6 million doses of...